PET/CT offers excellent accuracy in the staging of high-risk prostate cancer (PCa), yet outcomes-based evidence of the clinical benefit remains limited. We aimed to determine whether the rates of ...
SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...
ROCHESTER, Minn. — To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department ...
There are no well-established re-treatment options for local recurrence after primary curative radiation therapy for prostate cancer (PCa), as prospective studies with long-term follow-up are lacking.
Longer time to relapse is associated with a decreased risk of dying from prostate cancer. PSA recurrence (PSAR) more than five years after radical prostatectomy for prostate cancer is associated with ...
Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...
After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...
Once these scans are performed, it is imperative to evaluate the PSA values for a trend. Several studies [3,4] have sought to clarify the impact of rising PSAs based on pretreatment characteristics ...
Dear Dr. Roach: I am a healthy 89-year-old United States Army veteran. In August 2017, I was diagnosed with advanced prostate cancer and was treated with Lupron and radiation. These treatments have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results